Acute myeloid leukemia: 2013 update on risk-stratification and management

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia

(2012) A. Quintas-Cardama et al.   BLOOD

Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia

(2012) W. Leung et al.   BLOOD

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

(2012) J. A. L. Yin et al.   BLOOD

Reduction in WT1 Gene Expression During Early Treatment Predicts the Outcome in Patients With Acute Myeloid Leukemia

(2012) Charlotta Andersson et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia

(2012) Krzysztof Mrózek et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemtuzumab Ozogamicin: Time to Resurrect?

(2012) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study

(2012) Jerzy Holowiecki et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia

(2012) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial

(2012) Stefan Faderl et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of AML: resurrection for gemtuzumab ozogamicin?

(2012) Elihu Estey   LANCET

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

The rule of three in AML induction—is cladribine the answer?

(2012) Frederick R. Appelbaum   Nature Reviews Clinical Oncology

Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors

(2012) Claudio Anasetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pursuing the Goal of a Donor for Everyone in Need

(2012) Frederick R. Appelbaum   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management

(2011) Elihu H. Estey   AMERICAN JOURNAL OF HEMATOLOGY

Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation

(2011) M. Fang et al.   BLOOD

Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid

(2011) J. H. Park et al.   BLOOD

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia

(2011) F. Buccisano et al.   BLOOD

Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment

(2011) Roland B. Walter et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

(2011) Roland B. Walter et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

(2011) U Platzbecker et al.   LEUKEMIA

Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets

(2011) Giovanni Rossi et al.   LEUKEMIA RESEARCH

Cytarabine Dose for Acute Myeloid Leukemia

(2011) Bob Löwenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome

(2010) Marcos de Lima et al.   CANCER

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

(2010) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

(2010) Jeffrey E Rubnitz et al.   LANCET ONCOLOGY

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

(2010) W. Blum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Relapse and death during first remission in acute myeloid leukemia

(2008) M. Yanada et al.   HAEMATOLOGICA

Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype

(2008) Dimitri A. Breems et al.   JOURNAL OF CLINICAL ONCOLOGY